CompletedNot Applicable

Lidocaine IV Injection With Different Doses for Patients With Neuropathic Pain After Mastectomy

Egypt30 participantsStarted 2022-07-25

Plain-language summary

cancer has become the most common malignancy affecting women worldwide, and its incidence is increasing annually. According to the Global Cancer Observatory (GLOBOCAN) 2020 published by the International Agency for Research on Cancer of the World Health Organization, female breast cancer is the cancer with the highest number of new cases worldwide significant number of patients experiencing moderate to severe acute pain (30-50%) and developing chronic post-surgical pain (CPSP) (25-68%)

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18years. * Females with neuropathic pain following mastectomy for cancer breast. * American Society of Anesthesiologists (ASA) physical status I-III. * Patients on other drugs with intolerable side effects. * Patients undergoing breast surgery Exclusion Criteria: * Patients with known hypersensitivity to lidocaine. * Patients with history of uncontrolled seizures. * Patients with second- or third-degree heart block. * Patients with altered cognitive dysfunction.

What they're measuring

To assess neuropathic pain scale

Timeframe: assessed at 0, 15, 30, 1 hour. 2 hours and 24 hours and 1 week after injection

Trial details

NCT IDNCT07475520

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-25

View on ClinicalTrials.gov More Neuropathic Pain Induced by Mastectomy trials